EVR 6.7MSFT 0.71DAL 0.73JPM 10.04ATD.TO 0.76MTD 11.16CRWD -28.52
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.69
+0.35 (1.38%)
as of Jun 4, 2026, 8:00:00 pm Market Open.
579 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 4, 2026, 12:00 am

This summary was created by AI, based on 31 opinions in the last 12 months.

Pfizer Inc. (PFE) is currently facing significant challenges, primarily due to a patent cliff and a lack of earnings momentum following the COVID-19 pandemic. Many experts express concerns over its drug pipeline, indicating that the company is in need of a blockbuster drug to drive future growth. While it maintains an attractive dividend yield—ranging from 6.4% to 7%—there is skepticism about the sustainability of this yield if new profitable drugs are not developed soon. The stock’s valuation is seen as low, trading at around 8-10 times earnings, which some experts believe might make it appealing for patient investors. However, the consensus also points to caution due to the industry-wide challenges, including cost-cutting measures and potential government pressure on drug pricing.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
NVO
PAST TOP PICK

Pfizer Inc(PFE)

Oct 31, 2006
(A Top Pick July 11/06. Up 12.8%.) 3.6 % dividend. Still more upside. But pipeline. Money continues to flow into the multinationals, which will benefit this company.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$26.65

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 23, 2006
3.4% dividend. The stock has been steadily rising over the last four months. Should be a core holding.
Photo of Rob CallanderRob Callander
Owned
Unlock Rating
$27.73

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Oct 19, 2006
This group has been forgotten over the last 5 years as it wildly under-performed the market. They all went to virtually zero growth rate and now there is a pick up. There is cost cutting and they are under owned. Likes this space. This would not be his number one choice but it is okay.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$27.68

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Oct 17, 2006
Reached his model price and he sold his holdings.
Photo of Brian Acker, CABrian Acker, CA
No
Unlock Rating
$27.72

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 16, 2006
Pipeline has been a little hurt because of competition, but the valuation is as cheap as it has been in 20 years.
Photo of John ZechnerJohn ZechnerUnlock Rating
$27.66

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 10, 2006
His favourite large drug stock. Has been beaten up pretty badly. Has a great product pipeline, even with patents coming off. Swimming in cash. Doing a share buyback and have increased their dividends.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$27.56

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 04, 2006
Very cheap. Pays a nice yield. There were some issues with management and there has been a change. The pharmaceutical industry as a whole is undervalued.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$28.33

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Sep 27, 2006
The stock has increased since he picked it. They have raised their dividends. It has a high yield. He continues to own.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$28.41

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 18, 2006
Good value for a bounce. Expects another 15/20% upside. Treating it as a Trade, not for the long term.
Photo of Ross HealyRoss Healy
Owned
Unlock Rating
$28.16

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 22, 2006
Likes it and still buying for new clients. Have a pipeline of new drugs and using their cash to develop new drugs. Have sold their consumer products division. Have increased their dividends and doing buybacks.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$26.98

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 17, 2006
His 2 favourite pharmaceuticals are Glaxosmithkline (GSK-N) and Johnson & Johnson (JNJ-N). This company is having so much trouble right now that they are on their 3rd CEO in the last 5/6 years. Have patent problems and sales are declining. Outstanding lawsuits.
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$27.00

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Aug 09, 2006
Big issue is 20% of revenue and a larger % of profits comes from one drug, Lipitor, which will get generic competition. Sold their consumer business and have other products in the pipeline and they are buying back mountains of its own stock. Dividend share is significant.
Photo of Brad WillockBrad Willock
No
Unlock Rating
$26.15

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Aug 03, 2006
A defensive position. Very cheap. Lots of value and seems to have momentum.
Photo of Ross HealyRoss Healy
Owned
Unlock Rating
$25.51

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Aug 02, 2006
(A Top Pick May 10/06. No change.) A large cap stock that is going into transition. Sold their consumer products area. Wants to see how this affects the balance sheet. 4% dividend. Still likes.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$25.61

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jul 25, 2006
All the major drug stocks are starting to act better. In the state of market, money moves from risky stocks to defensive stocks. Has a great yield. A good place to be.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$24.96

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
Showing 601 to 615 of 883 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

RY.TO 5.13$270.94
BHP -2.07$88.78
TA.TO -2.08$18
V 7.78$320.18
TOU.TO -0.12$65.42

Today's Top Picks

EVR 6.7$346.79
MSFT 0.71$428.05
DAL 0.73$79.51
JPM 10.04$310.89
ATD.TO 0.76$80.79

Popular Articles

Latest Sell Signals

PRL.TO 0.07$21.2
CNQ.TO -0.14$66.22
SHOP.TO 4.46$161.54
RIO -2.46$105.4
BB.TO 0.3$14.4

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Darren Sissons

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica